|
業務類別
|
Biotechnology |
|
業務概覽
|
Precigen Inc is a commercial-stage biopharmaceutical company focused on developing precision medicines to improve the lives of patients, targeting immuno-oncology, autoimmune disorders, and infectious diseases using its proprietary and complementary technology platforms. These platforms support the development of gene programs, delivery through viral, non-viral, and microbe-based approaches, and control of gene expression for safety and efficacy. Its key platforms include AdenoVerse immunotherapy and UltraCAR-T, supported by the UltraPorator device for rapid and cost-effective manufacturing. Its clinical pipeline includes PRGN-2009, PRGN-3005, PRGN-3006, and PRGN-3007. Its reportable segments are Biopharmaceuticals and Exemplar. |
| 公司地址
| 20374 Seneca Meadows Parkway, Germantown, MD, USA, 20876 |
| 電話號碼
| +1 301 556-9900 |
| 傳真號碼
| -- |
| 公司網頁
| http://www.precigen.com |
| 員工數量
| 47 |
| Mr. Harry Thomasian, Jr |
Chief Financial Officer and Principal Accounting Officer |
美元 488.00K |
30/04/2026 |
| Mr. Rutul R. Shah |
Chief Operating Officer |
美元 485.00K |
30/04/2026 |
| Dr. Helen Sabzevari, PhD |
Director, President and Chief Executive Officer |
美元 1.00M |
30/04/2026 |
| Mr. Phil Tennant |
Chief Commercial Officer |
美元 510.00K |
30/04/2026 |
| Mr. Donald P. Lehr |
Chief Legal Officer |
美元 575.00K |
30/04/2026 |
|
|
| Mr. Fred Hassan |
Independent Director |
30/04/2026 |
| Mr. Jeffrey B. Kindler, J.D. |
Independent Director |
30/04/2026 |
| Ms. Nancy Howell Agee |
Independent Director |
30/04/2026 |
| Dr. Helen Sabzevari, PhD |
Director, President and Chief Executive Officer |
30/04/2026 |
| Mr. Cesar L. Alvarez |
Independent Director |
30/04/2026 |
| Ms. Vinita D. Gupta |
Independent Director |
30/04/2026 |
| Mr. Steven Frank |
Independent Director |
30/04/2026 |
| Mr. James S. Turley |
Lead Independent Director |
30/04/2026 |
| Mr. Randal J. Kirk |
Executive Chairman of the Board |
30/04/2026 |
|
|
|
|
